183 related articles for article (PubMed ID: 16869816)
1. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.
Forgue ST; Phillips DL; Bedding AW; Payne CD; Jewell H; Patterson BE; Wrishko RE; Mitchell MI
Br J Clin Pharmacol; 2007 Jan; 63(1):24-35. PubMed ID: 16869816
[TBL] [Abstract][Full Text] [Related]
2. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
[TBL] [Abstract][Full Text] [Related]
3. Tadalafil pharmacokinetics in healthy subjects.
Forgue ST; Patterson BE; Bedding AW; Payne CD; Phillips DL; Wrishko RE; Mitchell MI
Br J Clin Pharmacol; 2006 Mar; 61(3):280-8. PubMed ID: 16487221
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
Montorsi F; Verheyden B; Meuleman E; Jünemann KP; Moncada I; Valiquette L; Casabé A; Pacheco C; Denne J; Knight J; Segal S; Watkins VS
Eur Urol; 2004 Mar; 45(3):339-44; discussion 344-5. PubMed ID: 15036680
[TBL] [Abstract][Full Text] [Related]
5. Tadalafil.
Curran M; Keating G
Drugs; 2003; 63(20):2203-12; discussion 2213-4. PubMed ID: 14498756
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
7. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.
Goldstein I; Kim E; Steers WD; Pryor JL; Wilde DW; Natanegara F; Wong DG; Ahuja S
J Sex Med; 2007 Jan; 4(1):166-175. PubMed ID: 17233782
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction.
Hatzichristou D; Gambla M; Rubio-Aurioles E; Buvat J; Brock GB; Spera G; Rose L; Lording D; Liang S
Diabet Med; 2008 Feb; 25(2):138-46. PubMed ID: 18290855
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Graefe-Mody U; Rose P; Retlich S; Ring A; Waldhauser L; Cinca R; Woerle HJ
Br J Clin Pharmacol; 2012 Jul; 74(1):75-85. PubMed ID: 22242621
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.
Porst H; Padma-Nathan H; Giuliano F; Anglin G; Varanese L; Rosen R
Urology; 2003 Jul; 62(1):121-5; discussion 125-6. PubMed ID: 12837435
[TBL] [Abstract][Full Text] [Related]
13. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries.
Buvat J; van Ahlen H; Schmitt H; Chan M; Kuepfer C; Varanese L
J Sex Med; 2006 May; 3(3):512-20. PubMed ID: 16681477
[TBL] [Abstract][Full Text] [Related]
15. Cialis (tadalafil): a new treatment for erectile dysfunction.
Minhas S; Kalsi JS; Ralph DJ
Hosp Med; 2003 Oct; 64(10):589-92. PubMed ID: 14584238
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?
Phelan M; Anzures-Cabrera J; Carlile DJ; Rowell L; Kuhlmann O; Arold G; Robson R; Bentley D
Clin Pharmacokinet; 2013 Apr; 52(4):255-65. PubMed ID: 23400900
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Martin P; Oliver S; Gillen M; Marbury T; Millson D
Clin Ther; 2015 Dec; 37(12):2823-36. PubMed ID: 26519231
[TBL] [Abstract][Full Text] [Related]
18. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.
Dresser MJ; Desai D; Gidwani S; Seftel AD; Modi NB
Int J Impot Res; 2006; 18(1):104-10. PubMed ID: 16307008
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study.
Hellstrom WJ; Gittelman M; Jarow J; Steidle C; McMurray J; Talley D; Watts S; Mitchell CL; McGill JM
Eur Urol; 2008 May; 53(5):1058-65. PubMed ID: 17945409
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
